Ireland· IE-PA-PA1986/067/001

Ezetimibe/Simvastatin Teva Pharma 10 mg/20 mg tablets

A octreotide product containing ezetimibe + simvastatin, registered in Ireland by Teva B.V.. The same ATC class is registered in 17 of our 19 countries.

ATC H01CB02

Checked against HPRA (Ireland) on September 28, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about ezetimibe + simvastatinAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Octreotide is registered in 17 of 19 countries.

Countries holding a registration under ATC H01CB02 (octreotide), each read from that country’s own register.

This record: Ireland, from HPRA (Ireland)
10 of them publish a price we can compare per daily dose

Search octreotide products by name

Octreotide · ATC H01CB02

17 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Italyprice
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of octreotide costs, country by country.

Normalised to the WHO defined daily dose (0.7 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Octreotide · price per daily dose (0.7 mg)

USD · FX 28 Sept 2026

CH Switzerland$41.46

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)

Active substance: Ezetimibe + Simvastatin
Manufacturer: Teva B.V.
Country: Ireland (IE)
ATC code: H01CB02
ATC class: Octreotide
Defined daily dose: 0.7 mg, P
Reimbursed: Not published by this register
Source register: HPRA (Ireland)
Last checked: September 28, 2026

Packs & prices · 1

ie_pa_number
PA1986/067/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

367 interactions on record for octreotide.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check octreotide against other medicines How interaction checks work

Octreotide · interactions on record

367 records

4 severe
151 moderate
4 minor
168 info

Most severe, free to view

LonafarnibA16AX20severe
PexidartinibL01EX15severe
BexaroteneL01XF03severe
BexarotenL01XX25severe

40 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Octreotide in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All octreotide products

Authorised across Europe · EMA

The same active substance is authorised in 21 EEA countries. Names it is sold under:

Austria · Ezesim, Ezetimib/Simvastatin Accord
Belgium · Ezetimib/Simvastatin Ab, Ezetimibe/Simvastatin Krka
Cyprus · Ezetimibe/Simvastatin Accord, Inegy
Czechia · Ezetimibe/Simvastatin Teva Cr, Glezisim
Germany · Ezesimin, Ezetimib Simvastatin Zentiva
Denmark · Ezetimib/Simvastatin Demo, Ezetimib/Simvastatin Hexal
Spain · Ezetimiba/Simvastatina Alter, Ezetimiba/Simvastatina Aurovitas
France · Ezetimibe/Simvastatine Accord, Ezetimibe/Simvastatine Almus
United Kingdom (Northern Ireland) · Ezetimibe/Simvastatin Accord Healthcare, Ezetimibe/Simvastatin Ascend Laboratories
Greece · Cildar Plus, Ezetimib/Simvastatin Mylan
Croatia · Inegy, Vasitimb
Hungary · Inegy
Iceland · Ezetimib/Simvastatin Krka, Inegy
Italy · Ezetimibe E Simvastatina Accord, Ezetimibe E Simvastatina Almus
Luxembourg · Ezetimib/Simvastatin Ratiopharm®, Ezetimibe/Simvastatine Eg
Netherlands · Ezetimibe/Simvastatin Aurobindo, Ezetimibe/Simvastatine Cf
Norway · Ezetimib/Simvastatin Glenmark, Ezetimib/Simvastatin Krka
Portugal · Inegy, Sinvastatina + Ezetimiba Alter
Sweden · Ezetimib/Simvastatin Krka, Ezetimibe/Simvastatin Accord
Slovenia · Inegy, Vasitimb
Slovakia · Cornusan, Ezetimib/Simvastatín Teva B.V.

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/f6e40386-3c4d-433e-98fe-59afb2922991
GET /v1/drugs/f6e40386-3c4d-433e-98fe-59afb2922991?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "H01CB",
    "H01CB02"
  ],
  "strength": null,
  "pa_number": "PA1986/067/001",
  "substances": [
    "Ezetimibe",
    "Simvastatin"
  ],
  "legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
  "market_info": "Marketed",
  "authorised_at": "16/12/2016",
  "dispensing_status": "Product subject to prescription which may be renewed (B)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": "IC0034-051-002"
}

API reference MCP server Plans

See everything about octreotide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console